{"prompt": "['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', 'information which might influence the evaluation of the benefits and risks of a Pfizer', 'product, Pfizer should be informed immediately.', 'In addition, the investigator will inform Pfizer immediately of any urgent safety measures', 'taken by the investigator to protect the study patients against any immediate hazard, and of', 'any serious breaches of this NI study protocol that the investigator becomes aware of.', 'CONFIDENTIAL', 'Page 44 of 64']['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', '16. REFERENCES', '1.', 'Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the', 'incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota,', '1955-2007. Arthritis Rheum. 2010 Feb 26;62(6):1576-82.', '2.', 'Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al.', 'Estimates of the prevalence of arthritis and other rheumatic conditions in the United', 'States. Part I. Arthritis Rheum. 2008 Jan;58(1):15-25', '3.', 'Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010', 'Rheumatoid arthritis classification criteria: an American College of', 'Rheumatology/European League Against Rheumatism collaborative initiative.', 'Arthritis Rheum. 2010 Sep;62(9):2569-81.', '4.', 'Prete M, Racanelli V, Digiglio L, Vacca A, Dammacco F, Perosa F. Extra-articular', 'manifestations of rheumatoid arthritis: An update. Autoimmun Rev. 2011', 'Dec;11(2):123-31.', '5.', 'van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garc\u00eda Meijide J a, Wagner', 'S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J', 'Med. 2012 Aug 9;367(6):508-19.', '6.', 'Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B,', 'et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with', 'active rheumatoid arthritis with an inadequate response to tumour necrosis factor', 'inhibitors: a randomised phase 3 trial. Lancet. Elsevier Ltd; 2013 Feb', '9;381(9865):451-60.', '7.', 'van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al.', 'Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving', 'methotrexate: twelve-month data from a twenty-four-month phase III randomized', 'radiographic study. Arthritis Rheum. 2013 Mar;65(3):559-70', '8.', 'Kremer J, Li Z-G, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al.', 'Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs', 'in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med.', '2013 Aug;159(4):253-61.', '9.', 'Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell C a, Bradley JD, et al.', 'Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J', 'Med [Internet]. 2012 Aug 9 [cited 2014 Oct 15];367(6):495-507. Available from:', 'http://www.ncbi.nlm.nih.gov/pubmed/22873530', '10.', 'Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al.', 'Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014', 'Jun;370(25):2377-86.', '11.', 'Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and', 'efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid', 'arthritis in open-label, longterm extension studies. J Rheumatol. 2014', 'May;41(5):837-52.', 'Page 45 of 64']['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', '12.', 'Jacobi CE, van den Berg B, Boshuizen HC, Rupp I, Dinant HJ, van den Bos GAM.', 'Dimension-specific burden of caregiving among partners of rheumatoid arthritis', 'patients. Rheumatology (Oxford). 2003 Oct;42(10):1226-33.', '13.', 'Brouwer WBF, van Exel NJA, van de Berg B, Dinant HJ, Koopmanschap MA, van', 'den Bos GAM. Burden of caregiving: evidence of objective burden, subjective', 'burden, and quality of life impacts on informal caregivers of patients with', 'rheumatoid arthritis. Arthritis Rheum. 2004 Aug;51(4):570-7.', '14.', 'Smolen J, Ledenw\u00e9 R, Breedveld F. EULAR recommendations for the management', 'of rheumatoid arthritis with synthetic and biological disease-modifying', 'antirheumatic drugs. Ann Rheum Dis. 2010;69:964-75.', '15.', 'Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012', 'update of the 2008 American College of Rheumatology recommendations for the use', 'of disease-modifying antirheumatic drugs and biologic agents in the treatment of', 'rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 May;64(5):625-39.', '16.', 'Ruffing V, Bingham C. Rheumatoid arthritis: Treatment. The Jhons Hopkins', 'Arthritis Center. 2013.', '17.', 'Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015', 'American College of Rheumatology Guideline for the Treatment of Rheumatoid', 'Arthritis. Arthritis Rheumatol (Hoboken, NJ) [Internet]. 2016 Jan;68(1):1 1-26.', 'Available from: http://www.ncbi.nlm.nih.gov/pubmed/26545940', '18.', 'Smolen JS, Landew\u00e9 R, Breedveld FC, Buch M, Burmester G, Dougados M, et al.', 'EULAR recommendations for the management of rheumatoid arthritis with synthetic', 'and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum', 'Dis. 2014 Mar;73(3):492-509.', '19.', 'Food and Drug Administration. Label Information XELJANZ. 2015.', '20.', 'Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health', 'assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9(5):789-93.', '21.', 'Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and', 'practical applications. Health Qual Life Outcomes. 2003 Jan; 1 (1):20.', '22.', 'Gonz\u00e1lez VM, Stewart A, Ritter PL, Lorig K. Translation and validation of arthritis', 'outcome measures into Spanish. Arthritis Rheum. 1995 Oct;38(10):1429-46', '23.', 'Citera G, Arriola MS, Maldonado-Cocco JA, Rosemffet MG, S\u00e1nchez MM, Go\u00f1i', 'MA, et al. Validation and crosscultural adaptation of an argentine spanish version of', 'the health assessment questionnaire disability index. J Clin Rheumatol. 2004', 'Jun;10(3):110-5.', '24.', 'EuroQol Group. EuroQol--a new facility for the measurement of health-related', 'quality of life. Health Policy [Internet]. 1990 Dec;16(3):199-208. Available from:', 'http://www.ncbi.nlm.nih.gov/pubmed/10109801', '25.', 'EQ-5D-3L official languages [Internet]. [cited 2016 Mar 21]. Available from:', 'http://www.euroqol.org/eq-5d-products/eq-5d-31.htm', 'Page 46 of 64']\n\n###\n\n", "completion": "END"}